VJET yields 312.45% · ABBV yields 3.06%● Live data
📍 VJET pulled ahead of the other in Year 1
Combined, VJET + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VJET + ABBV for your $10,000?
voxeljet AG provides three-dimensional (3D) printers and on-demand parts services to industrial and commercial customers in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. It operates in two segments, Systems and Services. The Systems segment develops, manufactures, and sells 3D printers. This segment also offers consumables, including particulate materials and proprietary chemical binding agents, maintenance contracts, extended warranty contracts, and spare parts. The Services segment prints on-demand parts for its customers, as well as creates parts, molds, cores, and models using 3D computer-aided design at its service center; and provides casting services. It serves automotive, aerospace, art and architecture, engineering, and consumer product end markets; foundries and suppliers; and universities and research institutes through its direct sales force and a network of sales agents. The company was formerly known as Voxeljet Technology GmbH and changed its name to voxeljet AG in January 2004. voxeljet AG was founded in 1999 and is headquartered in Friedberg, Germany.
Full VJET Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.